WuXi Biologics
Offering End-to-End Solutions
WuXi Biologics applies a scale-out instead of a scale-up strategy to achieve higher volume production scales (see images below). Scale-out manufacturing offers more flexible manufacturing options especially in late-stage or commercial production scenarios.. Scale-out manufacturing utilizes multiple bioreactors run in parallel to produce late stage clinical material and market demand using the same size of bioreactor as used in early stage clinical trials. The advantages are numerous and include:
Similar to the concept described above, WuXi Biologics utilizes small footprint, fully robotic and programmable, isolator-based fill systems to achieve a scale-out manufacturing strategy for drug product production. Scale-up risks are eliminated and flexible and adaptable production can be achieved as clinical or market demands change. In addition, the faster changeover between runs that can be achieved with these systems is another added benefit for multi-product and multi-use fill facilities.